What Do We Get from Recent Statin and CETP Inhibitors Trials?
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Recent clinical trials and meta-analyses have indicated that high-intensive statin treatment lowers low-density lipoprotein cholesterol (LDL-C) levels and reduces the risk of nonfatal cardiovascular (CV) events compared with moderate-intensity statin treatment. However, there are residual risks of CV events and safety concerns associated with high-intensity statin treatment. The Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) study showed that ezetimibe plus moderate-intensity statin therapy after acute coronary syndromes incrementally lowers LDL-C levels and improved CV outcomes compared with moderate-intensity statin therapy. However, despite the LDL-C-lowering effects, a substantial residual CV risk still remains, which includes other lipid abnormalities such as low high-density lipoprotein cholesterol (HDL-C). The most representative agents that primarily increase HDL-C are cholesteryl ester transfer protein (CETP) inhibitors. Until now, 4 CETP inhibitors, including torcetrapib, dalcetrapib, evacetrapib, and anacetrapib, have been introduced and all have significantly raised the HDL-C from 30% to 133%. However, the results for CV outcomes in clinical trials differed, based on the 4 agents. Torcetrapib increased the risk of CV events and total mortality in patients at high CV risk (ILLUMINATE trial). Dalcetrapib and evacetrapib did not result in lower rate of CV events in patients with recent acute coronary syndrome and high risk vascular disease, respectively (dal-OUTCOMES and ACCELERATE trials). However, anacetrapib significantly decreased the incidence of major coronary events in patients with atherosclerotic vascular disease (REVEAL trial). This topic summarizes the major results of recent statin and CETP inhibitor trials and provides framework to interpret and implement the trial results in real clinical practice.
Abstract
Recent clinical trials and meta-analyses have indicated that high-intensive statin treatment lowers low-density lipoprotein cholesterol (LDL-C) levels and reduces the risk of nonfatal cardiovascular (CV) events compared with moderate-intensity statin treatment. However, there are residual risks of CV events and safety concerns associated with high-intensity statin treatment. The Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) study showed that ezetimibe plus moderate-intensity statin therapy after acute coronary syndromes incrementally lowers LDL-C levels and improved CV outcomes compared with moderate-intensity statin therapy. However, despite the LDL-C-lowering effects, a substantial residual CV risk still remains, which includes other lipid abnormalities such as low high-density lipoprotein cholesterol (HDL-C). The most representative agents that primarily increase HDL-C are cholesteryl ester transfer protein (CETP) inhibitors. Until now, 4 CETP inhibitors, including torcetrapib, dalcetrapib, evacetrapib, and anacetrapib, have been introduced and all have significantly raised the HDL-C from 30% to 133%. However, the results for CV outcomes in clinical trials differed, based on the 4 agents. Torcetrapib increased the risk of CV events and total mortality in patients at high CV risk (ILLUMINATE trial). Dalcetrapib and evacetrapib did not result in lower rate of CV events in patients with recent acute coronary syndrome and high risk vascular disease, respectively (dal-OUTCOMES and ACCELERATE trials). However, anacetrapib significantly decreased the incidence of major coronary events in patients with atherosclerotic vascular disease (REVEAL trial). This topic summarizes the major results of recent statin and CETP inhibitor trials and provides framework to interpret and implement the trial results in real clinical practice.
참고문헌 (26)
- Catapano AL, "2016 ESC", EAS guidelines for the management of dyslipidemias, 2016, pp.37, 2999~3058
- Stone NJ, "2013 ACC", AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology, J Am Coll Cardiol, pp.2014, 63(25)[DOI]
- Cholesterol Treatment Trialists' (CTT) CollaborationBaigent C, "Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials", Lancet, 376, pp.1670~1681 (2010)[DOI]
- Preiss D, "Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis", JAMA, 305, pp.2556~2564 (2011)[DOI]
- Collins R, "Interpretation of the evidence for the efficacy and safety of statin therapy", Lancet, 388, pp.2532~2561 (2016)[DOI]
- Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndrome", N Engl J Med, 372, pp.2387~2397 (2015)[DOI]
- Gordon DJ, "High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies", Circulation, 79, pp.8~15 (1989)[DOI]
- Barter P, "HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events", N Engl J Med, 357, pp.1301~1310 (2007)[DOI]
- Kaur N, "Effect of HDL-raising drugs on cardiovascular outcomes: a systematic review and meta-regression", PLoS One, 9, pp.e94585~ (2014)[DOI]
- Tall AR, "Trials and tribulations of CETP inhibitors", Circ Res, 122, pp.106~112 (2018)[DOI]
- Ferri N, "Present therapeutic role of cholesteryl ester transfer protein inhibitors", Pharmacol Res, 128, pp.29~41 (2018)[DOI]
- Barter PJ, "Effects of torcetrapib in patients at high risk for coronary events", N Engl J Med, 357, pp.2109~2122 (2007)[DOI]
- Schwartz GG, "Effects of dalcetrapib in patients with a recent acute coronary syndrome", N Engl J Med, 367, pp.2089~2099 (2012)[DOI]
- Lincoff AM, "Evacetrapib and caradiovascular outcomes in high-risk vascular disease", N Engl J Med, 376, pp.1933~1942 (2017)[DOI]
- HPS3, "TIMI55-REVEAL Collaborative GroupBowman L", Effects of anacetrapib in patients with atherosclerotic vascular disease, 2017, pp.377, 1217~1227
- Tardif JC, "Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib", Circ Cardiovasc Genet, 8, pp.372~382 (2015)[DOI]
- Giugliano RP, "Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT", Circulation, 137, pp.1571~1582 (2018)[DOI]
- Garber AJ, "Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2017 executive summary", Endocr Pract, 23, pp.207~238 (2017)[DOI]
- Garber AJ, "Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2018 executive summary", Endocr Pract, 24, pp.91~120 (2018)[DOI]
- AIM-HIGH InvestigatorsBoden WE, "Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy", N Engl J Med, 365, pp.2255~2267 (2011)[DOI]
- Nicholls SJ, "Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: the ACCENTUATE trial", Atherosclerosis, 261, pp.12~18 (2017)[DOI]
- Luo M, "ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity", Sci Rep, 7, pp.2312~ (2017)[DOI]
- Lewis CE, "Defining the safety of anacetrapib, a CETP inhibitor, in patients at high risk for coronary heart disease: the DEFINE study", Curr Cardiovasc Risk Rep, 5, pp.109~112 (2011)[DOI]
- Khera AV, "Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis", N Engl J Med, 364, pp.127~135 (2011)[DOI]
- Rohatgi A, "HDL cholesterol efflux capacity and incident cardiovascular events", N Engl J Med, 371, pp.2383~2393 (2014)[DOI]
- Simic B, "Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase", Atherosclerosis, 257, pp.186~194 (2017)[DOI]